Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65 (vol 23, pg 857, 2016)

被引：0
|
作者：
Georgiadis, A.
Duran, Y.
Ribeiro, J.
Abelleira-Hervas, L.
Robbie, S. J.
Sunkel-Laing, B.
Fourali, S.
Gonzalez-Cordero, A.
Cristante, E.
Michaelides, M.
Bainbridge, J. W. B.
Smith, A. J.
Ali, R. R.
机构：
[1] UCL Institute of Ophthalmology,Department of Genetics
[2] NIHR Biomedical Research Centre at Moorfields Eye Hospital,undefined
来源：
GENE THERAPY | 2024年 / 31卷 / 9-10期
关键词：
D O I：
10.1038/s41434-024-00463-z
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：524 / 524
页数：1
相关论文
共 37 条
  • [31] Treatment of Leber Congenital Amaurosis Due to RPE65 Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial
    Hauswirth, William W.
    Aleman, Tomas S.
    Kaushal, Shalesh
    Cideciyan, Artur V.
    Schwartz, Sharon B.
    Wang, Lili
    Conlon, Thomas J.
    Boye, Sanford L.
    Flotte, Terence R.
    Byrne, Barry J.
    Jacobson, Samuel G.
    HUMAN GENE THERAPY, 2008, 19 (10) : 979 - 990
  • [32] Phase I Gene Therapy Trial in Israeli Patients with Leber Congenital Amaurosis Caused by a Founder RPE65 Mutation: Safety and Efficacy Update with Up to Two Years of Follow-up
    Banin, Eyal
    Obolensky, Alexey
    Hemo, Yitzhak
    Marks-Ohana, Devora
    Sela, Malka
    Yamin, Esther
    Hauswirth, William
    Jacobson, Samuel
    Sharon, Dror
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [33] Phase I gene therapy trial in Israeli patients with Leber Congenital Amaurosis caused by a founder RPE65 mutation: safety and efficacy update with up to three years of follow-up
    Banin, E.
    Obolensky, A.
    Hemo, Y.
    Marks-Ohana, D.
    Sela, M.
    Yamin, E.
    Hauswirth, W. W.
    Jacobson, S.
    Sharon, D.
    HUMAN GENE THERAPY, 2013, 24 (03) : A6 - A7
  • [34] Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy
    Weleber, Richard G.
    Pennesi, Mark E.
    Wilson, David J.
    Kaushal, Shalesh
    Erker, Laura R.
    Jensen, Lauren
    McBride, Maureen T.
    Flotte, Terence R.
    Humphries, Margaret
    Calcedo, Roberto
    Hauswirth, William W.
    Chulay, Jeffrey D.
    Stout, J. Timothy
    OPHTHALMOLOGY, 2016, 123 (07) : 1606 - 1620
  • [35] Gene therapy using self-complementary Y733F capsid mutant AAV2/8 restores vision in a model of early onset Leber congenital amaurosis
    Ku, Cristy A.
    Chiodo, Vince A.
    Boye, Sanford L.
    Goldberg, Andrew F. X.
    Li, Tiansen
    Hauswirth, William W.
    Ramamurthy, Visvanathan
    HUMAN MOLECULAR GENETICS, 2011, 20 (23) : 4569 - 4581
  • [36] Gene therapy reforms photoreceptor structure and restores vision in NPHP5-associated Leber congenital amaurosis (vol 29, pg 2456, 2021)
    Aguirre, Gustavo D.
    V. Cideciyan, Artur
    Dufour, Valerie L.
    Ripolles-Garcia, Ana
    Sudharsan, Raghavi
    Swider, Malgorzata
    Nikonov, Roman
    Iwabe, Simone
    Boye, Sanford L.
    Hauswirth, William W.
    Jacobson, Samuel G.
    Beltran, William A.
    MOLECULAR THERAPY, 2021, 29 (12) : 3528 - 3528
  • [37] Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial
    Bennett, Jean
    Wellman, Jennifer
    Marshall, Kathleen A.
    McCague, Sarah
    Ashtari, Manzar
    DiStefano-Pappas, Julie
    Elci, Okan U.
    Chung, Daniel C.
    Sun, Junwei
    Wright, J. Fraser
    Cross, Dominique R.
    Aravand, Puya
    Cyckowski, Laura L.
    Bennicelli, Jeannette L.
    Mingozzi, Federico
    Auricchio, Alberto
    Pierce, Eric A.
    Ruggiero, Jason
    Leroy, Bart P.
    Simonelli, Francesca
    High, Katherine A.
    Maguire, Albert M.
    LANCET, 2016, 388 (10045): : 661 - 672
1234